| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/S11926-018-0741-5 |
| P698 | PubMed publication ID | 29850957 |
| P50 | author | Cecilia Beatrice Chighizola | Q38544863 |
| Pier Luigi Meroni | Q38544871 | ||
| P2860 | cites work | Guidance for the practical management of the direct oral anticoagulants (DOACs) in VTE treatment | Q28076077 |
| New oral anticoagulants: their advantages and disadvantages compared with vitamin K antagonists in the prevention and treatment of patients with thromboembolic events | Q28080616 | ||
| A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS) | Q28174751 | ||
| International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS) | Q28292418 | ||
| Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients | Q33341941 | ||
| A pilot open-label phase II trial of rituximab for non-criteria manifestations of antiphospholipid syndrome | Q33404206 | ||
| Intravenous immunoglobulins and antiphospholipid syndrome: How, when and why? A review of the literature | Q33428311 | ||
| Antiphospholipid antibodies disappearance in primary antiphospholipid syndrome: Thrombosis recurrence. | Q33439468 | ||
| EULAR recommendations for women's health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and/or antiphospholipid syndrome | Q33731711 | ||
| 14th International Congress on Antiphospholipid Antibodies: task force report on antiphospholipid syndrome treatment trends | Q34400373 | ||
| Treatment of Thrombotic Antiphospholipid Syndrome: The Rationale of Current Management-An Insight into Future Approaches | Q35621012 | ||
| A systematic review of secondary thromboprophylaxis in patients with antiphospholipid antibodies | Q37020336 | ||
| Prosthetic heart valves in pregnancy: a systematic review and meta-analysis protocol | Q37554341 | ||
| A prospective open-label pilot study of fluvastatin on proinflammatory and prothrombotic biomarkers in antiphospholipid antibody positive patients | Q37702168 | ||
| The estimated frequency of antiphospholipid antibodies in young adults with cerebrovascular events: a systematic review | Q38221324 | ||
| Intensity of anticoagulation in the treatment of thrombosis in the antiphospholipid syndrome: a meta-analysis | Q38273875 | ||
| Autoimmune Diseases Induced By Biological Agents. A review of 12731 cases (BIOGEAS Registry). | Q38601893 | ||
| Long-term use of hydroxychloroquine reduces antiphospholipid antibodies levels in patients with primary antiphospholipid syndrome | Q39608521 | ||
| Longterm Outcome of Patients with Primary Antiphospholipid Syndrome: A Retrospective Multicenter Study | Q40188551 | ||
| Prevention of thrombosis relapse in antiphospholipid syndrome patients refractory to conventional therapy using intravenous immunoglobulin. | Q41929738 | ||
| Regional anesthesia in the patient receiving antithrombotic or thrombolytic therapy: American Society of Regional Anesthesia and Pain Medicine Evidence-Based Guidelines (Third Edition). | Q43201516 | ||
| Morbidity and mortality in the antiphospholipid syndrome during a 5-year period: a multicentre prospective study of 1000 patients | Q43519903 | ||
| A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome | Q44588720 | ||
| Antithrombotic effects of hydroxychloroquine in primary antiphospholipid syndrome patients | Q44830352 | ||
| Low levels of vitamin D are common in primary antiphospholipid syndrome with thrombotic disease | Q46653559 | ||
| Anticoagulation treatment withdrawal in primary antiphospholipid syndrome when anticardiolipin antibodies become negative | Q46753205 | ||
| Protocol Modification of Apixaban for the Secondary Prevention of Thrombosis Among Patients With Antiphospholipid Syndrome Study. | Q48092335 | ||
| Vitamin D and antiphospholipid syndrome: A retrospective cohort study and meta-analysis. | Q50065600 | ||
| Can we withdraw anticoagulation in patients with antiphospholipid syndrome after seroconvertion? | Q50128278 | ||
| Cessation of oral anticoagulants in antiphospholipid syndrome. | Q50765317 | ||
| Stents Coated With Mammalian Target of Rapamycin Inhibitors (mTOR) Appear to Be the Best Choice in Patients With Antiphospholipid Syndrome and Myocardial Infarction. | Q51228431 | ||
| Discontinuation of anticoagulation or antiaggregation treatment may be safe in patients with primary antiphospholipid syndrome when antiphospholipid antibodies became persistently negative. | Q51252221 | ||
| Management of Thrombotic Antiphospholipid Syndrome. | Q53449116 | ||
| Inhibition of the mTORC pathway in the antiphospholipid syndrome. | Q55072769 | ||
| Vitamin D: an instrumental factor in the anti-phospholipid syndrome by inhibition of tissue factor expression | Q82081772 | ||
| Complement activation in antiphospholipid syndrome and its inhibition to prevent rethrombosis after arterial surgery | Q86868173 | ||
| Recurrent thrombosis in patients with antiphospholipid antibodies and arterial thrombosis on antithrombotic therapy | Q89777587 | ||
| P433 | issue | 7 | |
| P921 | main subject | thrombosis | Q261327 |
| P304 | page(s) | 44 | |
| P577 | publication date | 2018-05-31 | |
| P1433 | published in | Current Rheumatology Reports | Q23930052 |
| P1476 | title | Thrombosis and Anti-phospholipid Syndrome: a 5-Year Update on Treatment | |
| P478 | volume | 20 |
| Q89453447 | Seronegative antiphospholipid syndrome: refining the value of "non-criteria" antibodies for diagnosis and clinical management | cites work | P2860 |
Search more.